Fate Therapeutics beats earnings by $0.02, revenue tops estimates
Biotech firm reports adjusted profit of $0.09 per share, beating forecasts by $0.02, as revenue rose 18% year-on-year.
Fate Therapeutics reported adjusted earnings of $0.09 per share for the quarter, exceeding analyst expectations by $0.02, while revenue totaled $22.4 million, up 18% from the same period last year.
The San Diego-based biotech company attributed the revenue growth to increased demand for its cell therapy pipeline, particularly in oncology and autoimmune disease programs. Adjusted net income reached $12.1 million, compared with a net loss of $34.5 million in the prior-year quarter.
Analysts had projected adjusted earnings of $0.07 per share on revenue of $21.8 million, according to a Refinitiv consensus. Fate’s shares rose 3.2% in after-hours trading following the results.
The company reaffirmed its full-year guidance, projecting revenue of $90 million to $100 million and adjusted net income of $40 million to $50 million. Fate Therapeutics continues to advance its allogeneic cell therapy programs, with multiple clinical trials ongoing across various indications.
Management highlighted progress in its FT596 and FT516 programs, both targeting hematologic malignancies, as key drivers of the revenue increase. The company expects to report additional clinical data in the coming quarters.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →